Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clinical testing in colorectal cancer and other tumor types. A patient with metastatic colorectal cancer harboring an LMNA–NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance. To characterize the molecular bases of the patient's relapse, circulating tumor DNA (ctDNA) was collected longitudinally during treatment, and a tissue biopsy, obtained before entrectinib treatment, was transplanted in mice (xenopatient), which then received the same entrectinib regimen until resistance developed. Genetic profiling of ctDNA and xenopatient samples showed acquisition of two point mutations in the catalytic domain of NTRK1, p.G595R and p.G667C. Biochemical and pharmacologic analysis in multiple preclinical models confirmed that either mutation renders the TRKA kinase insensitive to entrectinib. These findings can be immediately exploited to design next-generation TRKA inhibitors. Significance: We provide proof of principle that analyses of xenopatients (avatar) and liquid biopsies allow the identification of drug resistance mechanisms in parallel with clinical treatment of an individual patient. We describe for the first time that p.G595R and p.G667C TRKA mutations drive acquired resistance to entrectinib in colorectal cancers carrying NTRK1 rearrangements.

Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer

RUSSO, MARIANGELA
Co-first
;
MISALE, SANDRA;SIRAVEGNA, GIULIA;CRISAFULLI, GIOVANNI;LAZZARI, LUCA;Rospo, Giuseppe;DI NICOLANTONIO, Federica;BARDELLI, Alberto
Co-last
2016

Abstract

Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clinical testing in colorectal cancer and other tumor types. A patient with metastatic colorectal cancer harboring an LMNA–NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance. To characterize the molecular bases of the patient's relapse, circulating tumor DNA (ctDNA) was collected longitudinally during treatment, and a tissue biopsy, obtained before entrectinib treatment, was transplanted in mice (xenopatient), which then received the same entrectinib regimen until resistance developed. Genetic profiling of ctDNA and xenopatient samples showed acquisition of two point mutations in the catalytic domain of NTRK1, p.G595R and p.G667C. Biochemical and pharmacologic analysis in multiple preclinical models confirmed that either mutation renders the TRKA kinase insensitive to entrectinib. These findings can be immediately exploited to design next-generation TRKA inhibitors. Significance: We provide proof of principle that analyses of xenopatients (avatar) and liquid biopsies allow the identification of drug resistance mechanisms in parallel with clinical treatment of an individual patient. We describe for the first time that p.G595R and p.G667C TRKA mutations drive acquired resistance to entrectinib in colorectal cancers carrying NTRK1 rearrangements.
6
1
36
44
http://cancerdiscovery.aacrjournals.org/content/6/1/36.full.pdf
Oncology, DROPLET DIGITAL PCR, COLON CANCER, REARRANGEMENTS, ENTRECTINIB
Russo, Mariangela; Misale, Sandra; Wei, Ge; Siravegna, Giulia; Crisafulli, Giovanni; Lazzari, Luca; Corti, Giorgio; Rospo, Giuseppe; Novara, Luca; Mussolin, Benedetta; Bartolini, Alice; Cam, Nicholas; Patel, Roopal; Yan, Shunqi; Shoemaker, Robert; Wild, Robert; Di Nicolantonio, Federica; Sartore-Bianchi, Andrea; Li, Gang; Siena, Salvatore; Bardelli, Alberto
File in questo prodotto:
File Dimensione Formato  
2016_Russo_Bardelli_CancerDiscov_Article&SI.pdf

Accesso riservato

Descrizione: Articolo principale (PDF Editoriale) e dati supplementari
Tipo di file: PDF EDITORIALE
Dimensione 3.58 MB
Formato Adobe PDF
3.58 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Russo_entrectinib_resistance_accepted_manuscript_2015_4aperto.pdf

Accesso aperto con embargo fino al 31/01/2017

Descrizione: Main article & Supplementary Information
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 7.04 MB
Formato Adobe PDF
7.04 MB Adobe PDF Visualizza/Apri
36.full.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 8.78 MB
Formato Adobe PDF
8.78 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1573112
Citazioni
  • ???jsp.display-item.citation.pmc??? 109
  • Scopus 213
  • ???jsp.display-item.citation.isi??? 209
social impact